Monoclonal Antibodies and Immunogenicity: Relevance to Clinical Practice?

Program Introduction

Technologies Used to Produce Therapeutic mAbs

Molecular Structures of Biologic Drugs Used to Treat Psoriasis

Biologics: Consequences of ADAs

Consequences of ADAs

Biologics: Types of ADAs

Relationship of Developing ADAs to Type of mAb

Immunogenicity of IL-17a and IL-12/23 Antibodies Are Low vs Other mAbs

Ixekizumab TE-ADAs Reported in the Phase 3 UNCOVER Trials

Relevance of ADAs for Treatment Strategies With Human or Chimeric Antibodies

Concluding Remarks

Abbreviations